Long term control of luteinized thecoma with sclerosing peritonitis with leuprorelin and tamoxifen treatment

Gynecol Oncol Rep. 2019 Feb 16:28:44-46. doi: 10.1016/j.gore.2019.02.004. eCollection 2019 May.

Abstract

Background: Luteinized thecoma with sclerosing peritonitis (LTSP) is a very rare condition, and its clinical management is not evidence-based. Here we describe a case of long-term disease control achieved with leuprorelin and tamoxifen therapy.

Case presentation: A 18-year-old woman with acute abdomen underwent surgical removal of an ovarian mass and received diagnosis of LTSP. Treatment plan consisted of leuprorelin and tamoxifen, followed by a good instrumental response. After 5 years, leuprorelin was stopped, and the patient continued tamoxifen alone. Ten years after diagnosis, she is still disease free.

Conclusion: Even in the absence of solid evidence, the combination of leuprorelin and tamoxifen could be considered as a possible medical treatment of LTSP. Considering the limitations related to the rarity of disease, further studies are needed to improve its management.

Keywords: Hormonal; Ovary; Peritonitis; Sclerosing; Thecoma; Therapy.

Publication types

  • Case Reports